Man Group’s Cardiff Oncology CRDF Stock Holding History

Man Group’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-53,357	Closed	-$118K	–	2006
2024 Q2	$118K	Sell	53,357 -59,399	-53%	-$224K	﹤0.01%	1950
2024 Q1	$602K	Buy	+112,756	New	+$300K	﹤0.01%	1724
2023 Q3	–	Hold	0	–	–	–	1841

Other funds holding CRDF

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Man Group's CRDF Position: Q3 2024 in Review

Man Group sold out of Cardiff Oncology (CRDF) in Q3 2024, closing a stake of 53,357 shares — an estimated $118K sold.

Man Group first reported a position in CRDF in Q1 2024 and held it in 2 quarters. The position peaked at $602K in Q1 2024. 83 funds tracked by Wall St. Rank hold CRDF as of Q3 2024.

Man Group reported no remaining Cardiff Oncology position as of Q3 2024 after selling out during the quarter.
Man Group sold 53,357 Cardiff Oncology shares in Q3 2024, an estimated $118K.
Man Group first reported a position in Cardiff Oncology in Q1 2024 and held it in 2 quarters.
Man Group's Cardiff Oncology position peaked at $602K in Q1 2024.
83 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2024.

Based on Man Group's 13F filing for Q3 2024, filed 14 Nov 2024.